Non-Hodgkin Lymphoma Trial

ECHELON-2, Study ID: SGN35-014


This trial is currently enrolling patients in the following locations:

Alabama

  • Birmingham

California

  • Burbank
  • Stanford

Connecticut

  • New Haven

Florida

  • Gainesville
  • Orlando

Georgia

  • Augusta

Illinois

  • Maywood

Iowa

  • Iowa City

Kansas

  • Westwood

Louisiana

  • Shreveport

Maryland

  • Baltimore

Massachusetts

  • Boston

Michigan

  • Ann Arbor

Minnesota

  • St. Louis Park

Missouri

  • St. Louis

New Jersey

  • Hackensack

New York

  • Bronx
  • New York
  • Rochester

Ohio

  • Cincinnati
  • Cleveland
  • Columbus

Oklahoma

  • Oklahoma City

Pennsylvania

  • Philadelphia

Tennessee

  • Nashville

Texas

  • Dallas
  • Houston

Virginia

  • Charlottesville
  • Richmond

Washington

  • Seattle

Australia

  • Adelaide, SA
  • Chermside, Queensland
  • Clayton, Victoria
  • Concord, NSW
  • Darlinghurst, NSW
  • Footscray, Victoria
  • Heidelberg, Victoria
  • Newcastle, NSW

Canada

  • Edmonton, AB
  • Vancouver, BC

Czech Republic

  • Brno
  • Hradec Králové
  • Ostrava
  • Praha 2
  • Praha 10

Denmark

  • Arhus
  • Copenhagen
  • Odense
  • Roskilde

France

  • Caen Cedex 05
  • Créteil
  • La Roche-sur-Yon
  • La Tronche
  • Lille Cedex
  • Limoges
  • Nantes
  • Paris
  • Pessac
  • Pierre Benite
  • Poitiers
  • Rennes
  • Rouen

Germany

  • Berlin
  • Chemnitz
  • Frankfurt
  • Freiburg
  • Göttingen
  • Hamburg
  • Heidelberg
  • Jena
  • Koln
  • München
  • Nürnberg
  • Saar
  • Ulm

Hungary

  • Kaposvár
  • Szombathely

Israel

  • Be'er Sheva
  • Haifa
  • Jerusalem
  • Petach Tikva
  • Tel Aviv

Italy

  • Bergamo
  • Bologna
  • Brescia
  • Catania
  • Genova
  • MIlano
  • Pavia
  • Pesaro
  • Roma
  • Rozzano
  • Torino
  • Verona

Japan

  • Chuo-ku
  • Fukuoka
  • Isehara
  • Kashiwa
  • Koto
  • Kyoto
  • Maebashi
  • Nagoya
  • Okayama
  • Sendai
  • Suita

Korea

  • Seoul

Poland

  • Brzozow
  • Chorzow
  • Gliwice
  • Kraków
  • Warsaw

Romania

  • Brasov
  • Bucuresti

South Korea

  • Daegu
  • Seongnam-si
  • Seoul

Spain

  • Barcelona
  • León
  • Madrid
  • Salamanca
  • Sevilla
  • Valencia

Taiwan

  • Kaohsiung
  • Taichung
  • Tainan City
  • Taoyuan

United Kingdom

  • Cambridge
  • Leicester
  • London
  • Manchester
  • Newcastle upon Tyne
  • Nottingham

For further information, please call: 866-333-7436 or email clinicaltrials@seagen.com. Your message will be returned by the next business day.

Updated August 12, 2014

Study Name

A phase 3 randomized, double-blind clinical trial comparing brentuximab vedotin plus CHP (cyclophosphamide, doxorubicin, prednisone) with the standard-of-care CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) in the frontline treatment of patients with CD30-positive mature T-cell lymphomas.

What is a phase 3 study?

A phase 3 study normally involves more patients than a phase 2 trial and confirms the efficacy of the study drug and compares it to commonly used therapies. They also generate long-term safety data for the study drug.

In the SGN35-014 study, you will be given 6 to 8 cycles of treatment with either the chemotherapy CHOP or brentuximab vedotin plus CHP. You and your study doctor will not know which treatment combination you are given. This type of trial, in which the study treatments are not known, is called a “blinded” trial. You will have a 50-50 chance of receiving either CHOP or brentuximab vedotin plus CHP. This selection will be done by a computer.

Who can participate?

  • You are 18 or older.
  • You have been newly diagnosed with one of the following mature T-cell lymphoma subtypes: systemic anaplastic large cell lymphoma (sALCL), peripheral T-cell lymphoma – not otherwise specified (PTCL-NOS), angioimmunoblastic T-cell lymphoma (AITL), adult T-cell leukemia/lymphoma (ATLL; acute and lymphoma types only, must be positive for human T-cell leukemia virus 1), enteropathy-associated T-cell lymphoma (EATL), hepatosplenic T-cell lymphoma.
  • At a minimum, you are able to move around and are capable of self-care. You are up and about more than half of waking hours.
  • Lab tests meet a minimum requirement.
  • Other criteria apply. You will need to see a study doctor to determine if you are able to participate.

Why is the study being done?

This study is being done to test the safety and effectiveness of brentuximab vedotin in combination with CHP (cyclophosphamide, doxorubicin, prednisone) compared with the standard-of-care CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) in patients with mature T-cell lymphomas. At the end of the study, the two groups of patients will be compared to see if there is a difference in the length of response to treatment and whether there are differences in the side effects seen in the two groups.

You are now leaving Seattle Genetics' site. Seattle Genetics does not necessarily endorse the organization associated with this link and takes no responsibility for the content contained therein. This resource link is for informational purposes only. Do you want to continue to the external site and leave SeattleGenetics.com?

No, return to SeattleGenetics.com

Yes, leave SeattleGenetics.com